Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SER-252 (PEOZ-apomorphine)
SER-252 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| SER-252 (PEOZ-apomorphine) | DRUG | SER-252 drug product consists of 20mg lyophilized apomorphine equivalent in SER-252 drug substance in a sterile vial for reconstitution with a diluent product containing 15mM acetate buffer at pH 6.0 and 7% trehalose to maintain final pH and isotonicity in the reconstituted product. |
| enFuse | DEVICE | The enFuse® device is a sterile, non-pyrogenic, user-filled, single-use, fixed-dose subcutaneous dose delivery system. |
SER-252 is an investigational small molecule being developed for Parkinson's disease, specifically for patients with motor fluctuations. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in patients with advanced Parkinson's disease.
SER-252 is a small molecule therapeutic being developed for Parkinson's disease. The specific molecular target of SER-252 has not been disclosed in available information. It is being studied for its potential to address motor fluctuations in patients with advanced Parkinson's disease.
SER-252 is being developed by AgeX Therapeutics, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of SER-252 in patients with Parkinson's disease and motor fluctuations.
SER-252 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is a single ascending dose study in patients with Parkinson's disease and motor fluctuations.
SER-252 is being evaluated in a Phase 1 clinical trial with the identifier NCT07422675. This is a single ascending dose study in patients with Parkinson's disease and motor fluctuations, with an enrollment of 40 participants. The trial is currently recruiting and is uncontrolled.
Yes, SER-252 is also known as SER-252 (PEOZ-apomorphine). This alternative name may be used in some contexts to refer to the same investigational drug being developed by AgeX Therapeutics for Parkinson's disease.